Un nouveau venu : le Réseau d’Investigation de l’Insulinothérapie Automatisée (R2IA)

Automated insulin delivery (AID) is currently experiencing rapid implementation. It represents a major advance in the management of type 1 diabetes. This mode of insulin therapy combines three elements: an insulin pump, a real-time continuous glucose monitoring, and algorithms for automated insulin delivery aiming at the optimization of glycemic control. Many questions are raised on its benefits and limitations on long-term in clinical practice, its technological development, the extension of its indications, its cost–efficiency ratio, to which answers will have to be provided by clinical studies. The Réseau d’Investigation de l’Insulinothérapie Automatisée (R2IA) has been founded in France in order to reach these objectives. Supported by France 2030 program and funded by the Agence Nationale de la Recherche (ANR), coordinated by the Assistance publique–Hôpitaux de Paris (AP–HP), this nation-wide network aims at supporting to work together public and private hospitals, independent diabetes practitioners, researchers and industrial partners, in order to settle multicenter studies and observatories, generate health data in usual practice and assess medico-economic impact of automated insulin delivery.